KINETIC MODELING OF LIPOSOME DEGRADATION IN SERUM - EFFECT OF SIZE AND CONCENTRATION OF LIPOSOMES IN-VITRO

被引:23
作者
HARASHIMA, H
OCHI, Y
KIWADA, H
机构
[1] Faculty of Pharmaceutical Sciences, University of Tokushima, Tokushima, 770, 1-78-1, Shomachi
关键词
LIPOSOMES; DEGRADATION; MODELING; 5(6)-CARBOXYFLUORESCEIN; SERUM; STABILITY; DRUG CARRIER; IN-VITRO; COMPLEMENT;
D O I
10.1002/bdd.2510150304
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study is to propose a new method for quantitative evaluation of liposome degradation in serum. The time course of liposome degradation in rat serum was monitored continuously, using 6(5)-carboxyfluorescein as an aqueous phase marker. The degradation curves exhibited three characteristic phases: lag time, degradation, and plateau. This curve was described by a kinetic model with three parameters: lag time (tau), first-order degradation rate constant (k), and maximum degradation (alpha). The rate and extent of the degradation of liposomes were evaluated separately in terms of k and alpha, respectively. The effects of size and concentration of liposomes on their degradation kinetics were examined using this method. Both k and alpha increased with increasing liposomal size. The increased affinity of larger liposomes for complement was suggested to increase both k and alpha. On the other hand, alpha decreased with increasing liposomal concentration without altering k. The decreased extent of degradation was considered to result from the depletion of complement components. There was no significant effect of size and concentration of liposomes on tau. Quantitative evaluation of the rate and extent of degradation of liposomes will provide deeper insights into the interaction between liposomes and serum components, and basic information on liposomes as potential drug carriers.
引用
收藏
页码:217 / 225
页数:9
相关论文
共 15 条
[1]   CONTRIBUTION OF COMPLEMENT-SYSTEM ON DESTABILIZATION OF LIPOSOMES COMPOSED OF HYDROGENATED EGG PHOSPHATIDYLCHOLINE IN RAT FRESH PLASMA [J].
FUNATO, K ;
YODA, R ;
KIWADA, H .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1103 (02) :198-204
[2]   STABILITY OF LIPOSOMES INVIVO AND INVITRO IS PROMOTED BY THEIR CHOLESTEROL CONTENT AND THE PRESENCE OF BLOOD-CELLS [J].
GREGORIADIS, G ;
DAVIS, C .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1979, 89 (04) :1287-1293
[3]   THE PHOSPHOLIPID COMPONENT OF SMALL UNILAMELLAR LIPOSOMES CONTROLS THE RATE OF CLEARANCE OF ENTRAPPED SOLUTES FROM THE CIRCULATION [J].
GREGORIADIS, G ;
SENIOR, J .
FEBS LETTERS, 1980, 119 (01) :43-46
[4]   KINETIC-ANALYSIS OF TISSUE DISTRIBUTION OF DOXORUBICIN INCORPORATED IN LIPOSOMES IN RATS .1. [J].
HARASHIMA, H ;
OHSHIMA, S ;
MIDORI, Y ;
YACHI, K ;
KIKUCHI, H ;
KIWADA, H .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1992, 13 (03) :155-170
[5]   DISTINCTION BETWEEN THE DEPLETION OF OPSONINS AND THE SATURATION OF UPTAKE IN THE DOSE-DEPENDENT HEPATIC-UPTAKE OF LIPOSOMES [J].
HARASHIMA, H ;
SAKATA, K ;
KIWADA, H .
PHARMACEUTICAL RESEARCH, 1993, 10 (04) :606-610
[6]   KINETIC MODELING OF LIPOSOME DEGRADATION IN BLOOD-CIRCULATION [J].
HARASHIMA, H ;
KUME, Y ;
YAMANE, C ;
KIWADA, H .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1993, 14 (03) :265-270
[7]  
HARASHIMA H, IN PRESS PHARM RES
[8]   EFFECT OF PARTICLE-SIZE AND CHARGE ON CLEARANCE RATES OF LIPOSOMES AND LIPOSOME ENCAPSULATED DRUGS [J].
JULIANO, RL ;
STAMP, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1975, 63 (03) :651-658
[9]  
MORGAN BP, 1990, COMPLEMENT CLIN ASPE, P1
[10]  
PANGBURN MK, 1983, J IMMUNOL, V131, P1930